<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588194</url>
  </required_header>
  <id_info>
    <org_study_id>Hospital Universitario</org_study_id>
    <nct_id>NCT04588194</nct_id>
  </id_info>
  <brief_title>Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia</brief_title>
  <official_title>Romiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Gomez Almaguer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate and response duration with the&#xD;
      combination of low-dose rituximab, romiplostim and high-dose dexamethasone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune thrombocytopenia is an autoimmune disorder characterized by formation of&#xD;
      autoantibodies against platelet antigens leading platelet destruction.&#xD;
&#xD;
      Corticosteroids increase the platelet count in about 80 percent of patients. However, many&#xD;
      patients have a relapse when the dose of corticosteroid is reduced. Debilitating side effects&#xD;
      are common in patients who require long-term corticosteroid therapy to maintain the platelet&#xD;
      count. Romiplostim, it is a small molecule agonist of the c-mpl (TpoR) receptor, which is the&#xD;
      physiological target of the hormone thrombopoietin, has been shown to be effectively raise&#xD;
      the platelet count in adult patients (aged 18 years and over) who have had their spleen&#xD;
      removed or where splenectomy is not an option and have received prior treatment with&#xD;
      corticosteroids or immunoglobulins, and these medicines did not work (refractory ITP). There&#xD;
      are a few case reports where romiplostim an option as first line treatment for IT.&#xD;
&#xD;
      The purpose of this study is to determine the response rate and response duration with the&#xD;
      combination of rituximab (100 mg weekly four weeks), romiplostim (2mcg/Kg four weekly) and&#xD;
      high-dose dexamethasone (40mg PO days 1-4) in untreated adult patients with &lt;30*109/L&#xD;
      platelet count diagnosed with immune thrombocytopenia.&#xD;
&#xD;
      A complete response is defined as an increase in platelet counts to &gt;150×109/L on two&#xD;
      consecutive occasions. A clinical response is defined as an increase in the platelet count&#xD;
      between &gt;30×109/L on two consecutive measures and no bleeding. Duration of response is&#xD;
      considered from the day of the initial administration to the first time of relapse (platelet&#xD;
      count &lt;30×109/L) or to time of analysis Patients will be evaluated each week during 4 weeks&#xD;
      and then every month for at least 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>28 days</time_frame>
    <description>Platelet counts to &gt;30×109/L on two consecutive occasions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>28 days</time_frame>
    <description>Platelet counts to &gt;100×109/L on two consecutive occasions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Romiplostim, Rituximab, Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <description>Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21</description>
    <arm_group_label>Romiplostim, Rituximab, Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 100 mg weekly days 1, 7, 14, 21</description>
    <arm_group_label>Romiplostim, Rituximab, Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg IV/PO days 1-4</description>
    <arm_group_label>Romiplostim, Rituximab, Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically confirmed immune thrombocytopenia (IT) Platelet count less than 30,000/mm3&#xD;
             on two occasions.&#xD;
&#xD;
          -  Subject ≥ 16 years&#xD;
&#xD;
          -  Subject has signed and dated written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment (only corticosteroids at dose or prednisone equivalent of 300 mg)&#xD;
&#xD;
          -  Performance status above or equal to 2.&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Previous splenectomy&#xD;
&#xD;
          -  Connective tissue disease&#xD;
&#xD;
          -  Autoimmune hemolytic anemia&#xD;
&#xD;
          -  Relapse&#xD;
&#xD;
          -  Active infection, sepsis or fever&#xD;
&#xD;
          -  Positive for hepatitis B virus or hepatitis C virus or human immunodeficiency virus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario J. Eleuterio González</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Gómez, MD</last_name>
    <phone>83486136</phone>
    <email>dgomezalmaguer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mónica Bustillos, MD</last_name>
    <phone>6142255724</phone>
    <email>moni.bm88@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Servicio de Hematología, Hospital Universitario &quot;Dr. José Eleuterio González&quot;, Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mónica Bustillos, MD</last_name>
      <phone>6142255724</phone>
      <email>moni.bm88@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Gómez-Almaguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perla R. Colunga-Pedraza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Cantú-Rodríguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>César H. Gutiérrez-Aguirre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luz Tarín-Arzaga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mónica Bustillos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, Gómez-De León A, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Tarín-Arzaga L, Hernández-Reyes J, Ruiz-Arguelles GJ. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014 Jun 19;123(25):3906-8. doi: 10.1182/blood-2014-01-549360. Epub 2014 May 6.</citation>
    <PMID>24802773</PMID>
  </results_reference>
  <results_reference>
    <citation>Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Sánchez-Cárdenas M. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013 Jun;90(6):494-500. doi: 10.1111/ejh.12102. Epub 2013 Apr 2.</citation>
    <PMID>23470153</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper N, Terrinoni I, Newland A. The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia. Ther Adv Hematol. 2012 Oct;3(5):291-8. doi: 10.1177/2040620712453596.</citation>
    <PMID>23616916</PMID>
  </results_reference>
  <results_reference>
    <citation>Vishnu P, Aboulafia DM. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. J Blood Med. 2016 May 25;7:99-106. doi: 10.2147/JBM.S80646. eCollection 2016. Review.</citation>
    <PMID>27307776</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>David Gómez Almaguer</investigator_title>
  </responsible_party>
  <keyword>thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

